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Cytosine Arabinoside reduces the numbers of 
granulocyte macrophage colony forming cells (GM-
CFC) and high proliferative potential colony forming 
cells (HPP-CFC) in vivo in mice
   Abstract
Background: Cytosine arabinoside (Ara-C) is an S-phase specific cytotoxic 
drug used in the treatment of malignancies. It is converted to Cytosine 
Arabinoside triphosphate (Ara-CTP) in the cell. Cytosine Arabinoside 
triphosphate, reversibly displaces deoxy cytidine triphosphate from DNA 
polymerase for incorporation into DNA.  This process leads to cell death. 
Objective: To investigate the in vivo effects of Ara-C on the Granulocyte 
Macrophage Colony Forming Cells (GM-CFC) and High Proliferative 
Potential Colony Forming Cells (HPP-CFC) respectively in mice.
Methodology: Ara-C (150mg/kg) was administered intraperitoneally (i.p) 
once to mice and bone marrow cells sampled on days 1, 3 and 6. 
Results: Ara-C reduced the numbers of both GM-CFC and HPP-CFC 
in the bone marrow.  HPP-CFCs were initially more sensitive to Ara-C 
treatment than GM-CFCs.  In the six days after treatment the effect on 
GM-CFC persisted, while there was a partial recovery in the number of 
HPP-CFCs. 
Conclusion: It is possible that Ara-C disturbs the stem cells niche by 
damaging the stromal cells of the bone marrow microenvironment. This 
would result in derangement of HPP-CFC proliferation.
Introduction
Cytosine arabinoside (Ara-C) is a drug used in the treatment 
of  leukaemias and lymphomas, always in combination with 
other drugs.  It works by interfering with pyrimidine synthesis 
in actively dividing cells, both normal and pathological. 
Better understanding of  the way that Ara-C affects various 
cell lines in the bone marrow may help us to devise improved 
ways of  deploying this drug in the management of  neoplastic 
disease.  In this study we have used a mouse model to analyse 
the differential effects of  Ara-C on two important precursor 
cell lines in the bone marrow.
The haematopoietic system is composed of  cells that 
are arranged in a hierarchy in terms of  primitiveness as 
well as differentiation potential. The pluripotent stem cell 
population and their progeny are surrounded by stromal cells 
in the bone marrow. The haematopioetic stem cell (Long 
term-Haematopoietic Stem Cell) population is believed 
to be mostly in quiescent state but has a high self-renewal 
potential due to the bone marrow microenvironment that 
preserves this cell population in a specific niche. Above 
the stem cells pool are progenitor cells (Short term- 
Haematopoietic Progenitor Cell) that are believed to have a 
high population of  cells in cell cycle1,2 with a great number 
of  them in a differentiated  state. Therefore, the stem 
cell population can become vulnerable to differentiation 
pressures if  the niche is damaged while the progenitor cell 
population is vulnerable due to a high rate of  cell turn over. 
Ara-C is an S-phase specific cytotoxic drug and it has been 
shown to induce K562, a human erythroleukaemic cell line 
that has stem cell potential, into erythroid differentiation3. 
Once Ara-C enters the cell, it is converted to its active 
form Cytosine Arabinoside triphosphate. This active form 
reversibly displaces deoxy cytidine triphosphate from DNA 
polymerase for incorporation into DNA, a  process that leads 
to formation of  damaged and abnormal DNA4,5. Because 
Ara-C kills cells that are actively dividing – neoplastic as 
well as normal cells – one of  the side effects of  the drug 
is myelo-suppression resulting in granulocytopenia, anaemia 
and thrombocytopenia6,7.   
The bone marrow microenvironment consists of  stromal 
cells that originate from mesenchymal stem cells8. In vitro 
studies have shown that mesenchymal stem cells produce a 
number of  cytokines and extracellular matrix proteins and 
they also express cell adhesion molecules, all of  which are 
involved in the regulation of  haematopoiesis both in vivo 
and in vitro9,10. In vitro studies have shown that Ara-C may 
irreversibly damage the bone marrow microenvironment by 
reducing the viable mesenchymal stem cells by about 20% 
at clinically relevant concentrations11. It is possible that 
mesenchymal stem cells might become vulnerable together 
with haematopoietic cells following Ara-C administration. 
This could result in the reduced ability of  stromal cells to 
sustain haematopoiesis during Ara-C administration.
The purpose of  this study was to investigate the effects of  
Cytosine Arabinoside (150mg/kg) on the haematopoietic 
pluripotent stem cells which are normally in a quiescent state 
as compared to the progenitor cells that have a large pool 
of  cells in cell cycle (Fig 1). We investigated changes in the 
numbers of  these two cell lines in mice after days, 1, 3 and 6 
following Ara-C (150mg/kg) drug administration.
Material and Methods
The bone marrow cells were plated in semi solid agar cultures 
according to established methods for assaying GM-CFC 
and HPP-CFC12,13. Previous work has shown that patients 
who receive the dose of  150mg/kg do not develop severe 
pancytopenia (14). All experiments were carried out using 
mice, regardless of  sex and weighing an average of  25 g, 
purchased from Thondwe in Zomba from a local farmer 
after approval from the College of  Medicine Research 
Ethics Committee (COMREC). In order to acclimatise 
the mice, they were kept in the laboratory for 2 weeks 
before experiments were conducted, and were looked after 
according to standard animal maintenance procedures. They 
were divided into two groups each consisting of  3 animals. 
One group was injected intraperitoneally with 150 mg/kg 
Ara-C dissolved in normal saline at day 0, and mice in the 
other group were injected with a similar volume of  normal 
saline to serve as controls.  One animal from each group was 
sacrificed (by cervical dislocation) at days 1, 3, and 6 after 
injection. No attempt was made to determine the number of  
nucleated bone marrow cells per femur. The percentage of  
HPP-CFC in S-phase was not investigated and is currently 
not known.
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Granulocyte-Macrophage Colony-Forming Cell 
(GM-CFC) Assay
Using a fine needle, pooled bone marrow cells were flushed 
with Dulbecco’s modified Eagle’s medium (Sigma,UK) 
supplemented with 20% horse serum (HS), 50 IU benzyl 
penicillin, 50 µg/ml streptomycin and 2mM L-glutamine 
(D20% HS PS/G). A final concentration of   105 cells/
ml was suspended in D20% HS PS/G with 0.3% melted 
agar (Bacto Agar, Difco Labs; Detroit, MI). 1ml of  cell 
suspension was plated in each non-tissue culture grade 
30-mm Petri dish (Sterilin; Stone, UK) in the presence of  
0.1ml of  L929 conditioned medium as a crude source of  
macrophage colony stimulating factor (M-CSF)(15).  Petri 
dishes were incubated in the fully humidified air/10% CO2 
incubator at 37O C (LEEC Ltd, UK) for seven days. At 
day six, the vital stain 2-(4-iodophenyl)-3-(4-nitrophenyl)-
5-phenyltetrazolium chloride (INT) (BDH Chemicals Ltd; 
Poole, UK) was added and stained colonies were counted 
macroscopically on day 7.
High Proliferative Potential Colony-Forming 
cell (HPP-CFC) Assay
Pooled bone marrow cells were grown over a feeder layer 
made up of  0.5% melted agar (Bacto Agar, Difco Labs) in 
D20% HS PS/G supplemented with WEHI-3B-and L929-
conditioned media used as crude source of  interleukin 3 
and macrophage-colony stimulating factor. A cellular layer 
was made up of  105 nucleated cells/ml in D20% HS PS/G 
with 0.3% melted Agar. Cultures were incubated in a fully 
humidified air/10% CO2 incubator at 37O C. On day 13, 
INT was added and colonies (>2mm) were counted on day 
14 macroscopically 12,13.
Statistical Analysis
Four independent experiments were performed for each 
group of  experiments. In total twenty-four mice were used 
for the experiments. Eight petri dishes were plated for each 
batch for GM-CFC (32 for Ara-C and 32 for Saline in total) 
and four petri dishes were plated for each batch for HPP-
CFC (16 for Ara-C and 16 for Saline in total). The statistical 
significance of  the results was determined by the unpaired 
Students’ t-test. A p-value of  0.05 or less was considered 
significant.
FIG. 1.  Numbers of GM-CFC per 105 nucleated cells in the bone 
marrow of mice injected intraperitoneally with 150mg/kg body 
weight of Ara-C (shaded bars) or with a similar volume of normal 
saline (open bars) on different days after treatment. On each of the 
sampling days, the mean number of GM-CFC colonies was signifi-
cantly less (p<0.001)   in the Ara-C treated group than the saline-
treated controls.  The colony numbers in Ara-C treated mice are not 
increasing with time.
Results
The effect of Cytosine Arabinoside (Ara-c) on 
GM-CFC numbers in vivo.
As can be seen in Fig.1, on each of  the sampling days there 
were fewer GM-CFC colonies in the petri dishes containing 
bone marrow cells from mice treated with Ara-C as compared 
to the mice treated with normal saline.  On each day the 
difference in mean number of  colonies between saline 
controls and Ara-C treated mice  was statistically significant 
with p-values of  less than 0.001.   There was no change in 
the mean count of  GM-CFC colonies between the three 
sampling days.
The effect of Cytosine Arabinoside on HPP-CFC 
numbers in vivo
As shown in Fig. 2, on day 1, only 4.0 ± 2.0 per 105 nucleated 
cells HPP-CFC colonies were grown from Ara-C treated mice 
compared to 108 ± 24.8 per 105 nucleated cells (p < 0.0001) 
from mice treated with normal saline. The mean number of  
colonies in Ara-C treated mice remained similar on day 3 but 
by day 6 had increased, although still significantly less than 
in the saline-treated group (p<0.01).  The increase in mean 
HPP-CFC colony counts in Ara-C treated mice between day 
1 and day 6 was highly significant (p<0.0001)
Comparison of the percentages change GM-
CFC from and HPP-CFC following Cytosine 
Arabinoside (150mg/kg intraperitoneally) 
treatment relative to Normal Saline controls.
Fig.3 presents the same figures but expresses the mean 
colony counts in Ara-C treated mice as a percentage of  the 
equivalent mean counts in saline-treated controls, for each of  
the three sampling days. There was a statistically significant 
difference in colonies numbers between GM-CFC and HPP-
CFC colonies in the Ara-C treated group on days 1 and 3 (p 
< 0.0001), with much lower mean counts for HPP-CFC than 
for GM-CFC. On day 6 there was no statistical significant 
difference between the colony numbers of  the two cell lines 
in Ara-C treated mice (p > 0.4).
Discussion
This study has shown that Ara-C reduces the number of  
progenitor and stem cells at both GM-CFC and HPP-CFC 
levels in vivo in a murine model. Several limitations of  the 
study need to be taken to consideration.  Owing to financial 
constraints, we did not determine the number of  nucleated 
cells per femur at the time of  sacrificing each animal; this 
figure would have enabled us to determine whether cell 
numbers are changing as well as colony numbers.  Nor did 
we identify the percentage of  HPP-CFC in S phase, to see 
the proportion of  these cells that would be vulnerable to 
Ara-C prior to treatment.   Despite these shortcomings, it is 
possible to consider other mechanisms that might account 
for the differential effects that we observed (a) in the impact 
of  Ara-C on GM-CFC and HPP-CFC cell populations and 
(b) in the recovery rates of  these different cell populations 
during the days after treatment. 
Possible explanations for behaviour of  GM-CFC after Ara-C 
therapy. Ara-C mainly targets cells that are in S-phase of  the 
cell cycle, and as 30% of  GM-CFCs are in cell cycle,12. 16-18 
the majority  of  GM-CFC might have been directly damaged 
following the treatment. Most of  these damaged cells can 
easily be replaced from the primitive haematopoietic cell 
population by direct recruitment. Primitive stem cells are 
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induced into cell cycle as well as produce progenitor cells 
that are mobilized from marrow to blood following cytotoxic 
treatment19-21. However, in the present study, the GM-CFC 
population has remained depressed partly because it has not 
been replaced by HPP-CFC proliferation . The period under 
investigation was not long enough for cell transition from 
the HPP-CFC compartment to the GM-CFC compartment. 
In absence of  HPP-CFC differentiation, the GM-CFC 
pool would remain low or depleted with time. This could 
explain in part the reduction of  GM-CFC numbers as the 
time progressed . However, one would expect a return to 
normal GM-CFC numbers with time as the HPP-CFC pool 
is recruited and replenishes the GM-CFC pool.
FIG. 2. Numbers of HPP-CFC per 105 nucleated cells in the bone 
marrow of mice injected intraperitoneally with 150mg/kg body 
weight of Ara-C (shaded bars) or with normal saline (open bars) on 
different days after treatment. HPP-CFC numbers are greatly reduced 
on day 1 in the Ara-C treated group, and there was a gradual increase 
in HPP-CFC numbers in this group over time, although the mean 
HPP-CFC count remained significantly lower than that in the saline 
group throughout the period of the study.
Effects of Ara-C on HPP-CFC
The effect of  Ara-C on HPP-CFC is however more difficult 
to explain. One would not expect a big change in the stem 
cell pool following Ara-C treatment as this cell population 
is believed to be quiescent with less than 10% of  HPP-CFC 
in cell cycle at any one time12. It is possible that a relatively 
high number of  HPP-CFC were already in cell cycle as the 
mice were not specific pathogen free. However, if  this were 
the case a relatively high proportion of  GM-CFC would 
have also been affected as the pathogens would not only 
have selectively recruited HPP-CFC but also GM-CFC. 
More plausible explanations for the huge drop in HPP-CFC 
counts in Ara-C treated mice include damage to the stromal 
cells of  bone marrow micro-environment which would lead 
to the destruction of  the niche of  HPP-CFC, HPP-CFC cell 
senescence;  and HPP-CFC apoptosis. Stromal cell damage 
would destroy the niche and allow stem cells to self  renew 
or differentiate, and hence (because now replicating) become 
directly vulnerable to the effects of  Ara-C. In addition, the 
destruction of  stromal cells would delay the ability of  stromal 
cells to produce stimulatory factors that work on GM-CFC 
recruitment such as macrophage colony stimulating factor 
(M-CSF) which are expressed by accessory cells of  bone 
marrow microenvironment for both osteoclastogenesis and 
macrophage maturation22. This in turn would reduce the 
recovery of  the GM-CFC compartment. Since there is a feed 
back loop in the recruitment of  both GM-CFC and HPP-
CFC cell population, the inability of  stromal cells to produce 
necessary factors crucial to keep the loop functional would 
result in delayed cell recovery in the GM-CFC while the 
HPP-CFC population would be under greater pressure to 
differentiate and self  renew. This would therefore explain in 
part the increase in numbers of  HPP-CFC over time and the 
constant numbers of  GM-CFC with time following Ara-C 
treatment. Others have shown that Ara-C damages the bone 
marrow stromal cells in vivo23.
FIG. 3. Mean numbers of of HPP-CFC and GM-CFC colonies in 
Ara-C treated mice expressed as percentage of mean colony numbers 
in controls.   This figure shows that there was a statistically significant 
difference in colonies numbers between normal Saline Control GM-
CFC and HPP-CFC colonies when compared to  the Ara-C treated 
group .
Proliferation kinetics of  cells is achieved by a series of  signal 
transduction pathway molecules which is usually triggered 
by cytokines. These cytokines work as both inhibitors and 
stimulators of  cell proliferation. Imbalance of  cytokines 
can therefore result in disruption of  the proliferation 
characteristics of  haematopoietic cells resulting in either 
cell senescence, apoptosis or cell proliferation. Cytotoxic 
drugs can induce cell senescence24 and also apoptosis25. In 
addition, Ara-C has been shown to accelerate recovery of  in 
vivo inhibition of  the bone marrow myeloid progenitor cells 
by myelosuppressive chemokines26. The effects of  Ara-C on 
HPP-CFC population in the present study have shown the 
complexity of  the Ara-C induced cell inhibition in vivo.
In conclusion, we have shown that Ara-C has a toxic effect 
on both GM-CFC and HPP-CFC. We suggest that the 
effect of  Ara-C on haematopoietic cells may be due in part 
to concomitant damage to  stromal cells. This effect could 
result in bone marrow damage if  repeated doses of  Ara-C 
are administered in vivo. There is need therefore for further 
studies to determine how  stromal cells might be protected 
from damage during treatment with Ara-C.  This will require 
further investigations of  the bone marrow microenvironment 
of  Ara-C treated mice – including both cellular and cytokine 
components –  using longer term bone marrow cultures. 
Acknowledgement
Special thanks go to The Third World Academy of  Sciences 
(TWAS) for funding this project. In addition, we are 
indebted to Dean of  University of  St. Andrews (Prof. R.H. 
MacDougall) for funding Tina Briscoe from St. Andrews 
University, Scotland who assisted us with establishment 
of  the tissue culture laboratory and for all her technical 
assistance. We are also grateful to Prof. A. Riches of  St. 
Andrews for providing the WEHi and L929 conditioned 
Malawi Medical Journal; 23(4): 105-109 December 2011 Cytosine Arabinoside 122
medium for culturing haematopoietic cells.
References
1.Tong Y, Linheng L. The stem cell niches in bone. Journal of Clinical 
Investigations 2006.; 116: 1195-1201
2. Passegue E, Wagers AJ, Giuriato S, Anderson WC, Weissman IL. 
Global analysis of proliferation and cell cycle gene expression in the 
regulation of haematopoietic stem and progenitor cell fates. Journal of 
Experimental Medicine 2005.; 2020:1599-1611
3. Luisi-Deluca C, Mitchell T, Spriggs D, Kufe DW. Induction of 
terminal differentiation in human K562 erythroleukaemia cells by 
arabinofuranosylcytosine. Journal of Clinical Investigations 1984.; 73: 
821-827
4. Major P, Egan EM, Hoerwick D, Kufe D. The effects of Ara-C 
incorporation on DNA synthesis. Biochemical Pharmacology 1982.; 
31: 2937-2940
5. Fram R, Kufe D.  DNA strand breaks caused by inhibitors of DNA 
synthesis 1-β-arabinofuranosylcytosine and aphidicolin. Cancer 
Research 1982.;  42: 4050-4053
6. Burnett AK, Hill RK, Milligan DW, Goldstone AH, Prentice AG, 
Mullin MF, Duncombe A, Gibson B, Wheatley K. Attempts to optimize 
induction and consolidation treatment in acute myeloid leukaemia. 
Results of MRC AML 12 trial. Journal of Clinical Oncology 2010.; 28: 
586-595
7. Jerushalmy Z, Patyta M, Pinkhas J, De Vries A. Alteration of rat 
bone marrow megakaryocytes following administration of cytosine 
arabinoside, daunomycin and hydroxyurea. Haemostasis 1977.; 6: 110-
117
8. Prockop D J. Marrow stromal cells as stem cells for nonhematopoietic 
tissues. Science 1997.; 276: 71-74
9. Conget PA, Minguell JJ. Phenotypical and functional properties of 
human bone marrow mesenchymal progenitor cells. Journal of Cell 
Physiology 1999.;  181:67-73
10. Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL. 
Phenotypic and functional comparison of cultures of marrow-derived 
mesenchymal stem cells and stromal cells. Journal of Cell Physiology 
1998.;  176:57-66
11. Jing Li, Law HKW, Lau L, Yu CG, Chi G. Differential damage 
and recovery of human mesenchymal stem cells after exposure to 
chemotherapeutic agents. British Journal Haematology 2004.; 127: 
326-334
12. Robinson S, Riches A. Haematopoietic stem cell proliferation 
regulators investigated using in vitro assay. Journal of Anatomy 1991.; 
174: 153-162
13. Chisi JE, Wdzieczak-Bakala J, Thierry J, Briscoe CV, Riches AC. 
Captopril inhibits the proliferation of haematopoietic stem cells and 
progenitor cells in murine long-term bone marrow cultures. Stem Cells 
1999.;  17: 339-344
14. Fanin R, Sperotto A, Ruizde Elvira C, Zaja F, Stocchi R, Geromin 
A, Cerno M, Patriarca F, Canelles MF, Damiani D, Bacarani M. A 
retrospective analysis of 144 patients with aggressive non-Hodgkin’s 
lymphoma: Impact of autologous stem cell transplantation in first 
remission on outcome. Haematologica 2000.;  85:943-951
15. Stanley E R, Heard PM. Factors regulating macrophage production 
and growth. Purification and some properties of the colony stimulating 
factor from medium conditioned by mouse L cells.  Journal of Biological 
Chemistry 1977.; 252: 4305-4312
16. Bradford GB, Williams B, Rossi R, Bertoncello I. Quiescence, 
cycling, and turnover in primitive hematopoietic stem cell compartment. 
Experimental Hematology 1997.;  25: 445-453
17. Cheshier SH, Morrison SJ, Liao X, Weissman IL. In vivo 
proliferation and cell cycle kinetics of long-term, hematopoietic stem 
cells. Proceedings  of the National Academy of Sciences USA 1999.; 
96: 3120-3125
18. Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes 
M, Scadden DT. Hematopoietic stem cell quiescence maintained by 
p12CIP1/WAF 1. Science 2000.; 287:1804-1808
19. Morrison SJ, Wright DE, Weissman IL. Cyclophosphamide/
granulocyte colony stimulating factor induces hematopoietic stem 
cells to proliferate prior to mobilization. Proceedings of the National 
Academy of Sciences USA 1997.; 94: 1908-1913
20. Neben S, Marcus K, Mauch P. Mobilization of hematopoietic stem 
and progenitor cell subpopulation from the marrow to blood of mice 
following cyclophosphamide and /or granulocyte colony stimulating 
factor. Blood 1993.;  81: 1960-1967
21. Uchida N, Friera AM, He. D, Reitsma MJ, Tsukamoto AS, Weissman 
IL. Hydroxyurea can be used to increase mouse c-kit+Thy-1.1(lo)Lin-/
loSca-1(+) hematopoietic cell number and frequency in cell cycle in 
vivo. Blood 1997.; 90: 4354-4362
22. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000.; 
289:1504-1508
23. Ben-Ishay Z, Barak V. Bone marrow stromal dysfunction in mice 
administered cytosine arabinoside. European Journal of Haematology 
2001., 66: 230-237 
24. Meng A, Wang Y, van Zant G, Zhou D. Ionizing radiation and 
busulfan induce premature senescence in murine bone marrow 
hematopoietic cells. Cancer Research 2003.; 63: 5414-5419
25. Domen J. The role of apoptosis in regulating hematopoiesis and 
hematopoietic stem cells. Immunology Research 2000.; 22:83-94
26. Broxmeyer HE, Pelus LM, Kim CH, Hangoc G, Cooper S, Hromas 
R. Synergistic inhibition in vivo of bone marrow myeloid progenitors 
by myelosuppressive chemokines and chemokine-accelerated recovery 
of progenitors after treatment of mice with Ara-C. Experimental 
Hematology 2006.; 34:1069-1077
